GET DAILY SIGNALSFractyl Health (GUTS): Analyst Price Target Suggests +500% Upside Potential
Key Takeaways
- The $5 central target reflects the average of recently updated, reverse-split-adjusted analyst price targets, which cluster between roughly $2 and $8.
- At a latest price near $0.81, reaching $5 would require a gain of roughly 500%, a very large move for a clinical-stage company.
- Analyst views are unusually divergent, ranging from a Hold with a $4 target to Buy ratings as high as $8, with some aggregators still showing older, unadjusted figures as high as $72.
- The strongest supports are positive REMAIN-1 pivotal data and a sharper strategic focus on the Revita procedure, while dilution, negative equity, and Nasdaq delisting risk are the biggest obstacles.
- GUTS completed a 1-for-12 reverse stock split in October 2026, which explains much of the confusing target data currently circulating.
- For deeper context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
Analyst Price Targets and Consensus View
Fractyl Health, Inc. (GUTS) is a clinical-stage metabolic therapeutics company, not an exchange-traded fund, so this analysis is built around equity analyst price targets rather than fund metrics. The target picture is complicated by a 1-for-12 reverse stock split effective in early October 2026, which reset the share count and price scale while some older forecasts lagged behind.
Among recently updated, reverse-split-adjusted targets, the range spans roughly $2 to $8. Morgan Stanley maintained a Hold rating with a $4 target in October 2026, Craig-Hallum maintained Buy with a $5 target, and H.C. Wainwright maintained Buy with an $8 target. Independent aggregators such as TipRanks and MarketBeat report a current average analyst price target near $5, with a low of $2 and a high of $8. Because a few aggregators still display pre-split figures as high as $72 (and intermediate values like $24), a naive consensus can appear far higher; the $5 figure used here reflects the average of the updated, post-split estimates rather than those stale entries. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock traded near $0.81 in early November 2026, giving the company a market capitalization of only about $11 million. Reaching the $5 central target would require an increase of roughly 500%, an exceptionally large move that is typical only of binary, data-driven biotech outcomes. The path to such a level would almost certainly depend on clinical and regulatory milestones rather than gradual fundamental progress, because the company currently records no product revenue and a trailing net loss of roughly $106 million.
What Could Support a Move Toward the Target
Fractyl's lead asset is Revita, an endoscopic procedure intended to help patients maintain weight loss after discontinuing GLP-1 therapies. In October 2026 the company reported positive six-month REMAIN-1 pivotal data showing Revita participants maintained about 80% of their GLP-1-induced weight loss versus 67% for sham (p=0.0023), a result that supports the durability thesis central to the bullish analyst targets. Management also announced a restructuring to concentrate resources on Revita, and insiders, including the CEO and directors, made open-market purchases in mid-2026, a modest signal of internal conviction. A large addressable market around post-GLP-1 weight maintenance underpins the highest price forecasts.
What Could Prevent the Target From Being Reached
The risks are substantial. Fractyl has no commercial revenue, roughly $61 million in debt against about $47 million in cash, and a negative book value, meaning the $5 target depends on future financing and successful clinical execution rather than current fundamentals. The company has already used a reverse split to address Nasdaq's minimum-price listing rules, and further dilution remains a live concern for a pre-revenue biotech. A restructuring announced in October 2026 also signals financial pressure, and the wide analyst range reflects genuine disagreement about whether Revita can become a commercially meaningful product.
Technical Levels and Market Structure
The stock has fallen roughly 94% over the past year, and its 50-day and 200-day moving averages sit well above the current price, indicating a deeply impaired long-term trend. The post-split 52-week range stretches from about $0.82 to $29.34, but the upper portion reflects pre-split pricing distortions. In practical terms, any sustained move toward $5 would first need to reclaim and hold levels far above the current price, with no meaningful nearby support zone beyond the recent lows. From what I see, this kind of technical setup often requires a major catalyst to break higher.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a 12-month research horizon, though for a distressed biotech the effective horizon is often tied to discrete catalysts rather than a calendar. The next earnings report is scheduled for November 12, 2026. Investors should monitor follow-up REMAIN-1 and REVEAL-1 data, cash runway and any financing announcements, Nasdaq listing compliance, restructuring updates, and further analyst target revisions as the reverse-split-adjusted forecasts settle. I’m watching this closely as the post-split data settles in.
AI Daily Buy/Sell Signals
In my own research, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a data-driven view on momentum shifts, especially for volatile names like this. These tools use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like Fractyl Health, such tools can help traders track shifts in momentum and structure more efficiently than manual screening alone. Traders interested in a systematic approach can use these signals to discover opportunities, monitor positions, and spot changing trends in real time.
Final Assessment
The question of whether Fractyl Health can reach $5 hinges on a clinical and financing story rather than a valuation story. The $5 central target, derived from the updated post-reverse-split analyst range of roughly $2 to $8, sits about 500% above the current price, a very large required move. Support rests on positive REMAIN-1 data and a narrowed focus on Revita, while the principal obstacles are negative equity, ongoing cash burn, delisting risk, and the possibility of further dilution. With analyst views spanning Hold at $4 to Buy at $8 and older unadjusted figures still distorting some consensus tools, investors should weigh the binary clinical outcome against the company's strained balance sheet, and monitor upcoming earnings and financing developments closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GUTS in -12.81% downward trend, falling for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GUTS declined for three days, in 160 of 173 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for GUTS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for GUTS just turned positive on November 02, 2026. Looking at past instances where GUTS's MACD turned positive, the stock continued to rise in 17 of 21 cases over the following month. The odds of a continued upward trend are 81%.
Following a +12.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 105 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-88.892) is slightly lower than the industry average of (3.498). P/E Ratio (-1.022) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement